📊 DNTH Key Takeaways
Is DNTH a Good Investment? Thesis Analysis
Dianthus Therapeutics is a pre-revenue biotech company burning significant cash with minimal revenue generation ($2M annually) and operating losses of $177.9M, indicating an early-stage development company far from profitability. The company's -$129.1M operating cash flow and -$129.3M free cash flow demonstrate unsustainable cash burn rates despite holding $51.1M in cash, providing only ~5 months of runway at current burn rates. Fundamental profitability and growth metrics are severely negative, with no clear path to revenue generation evident.
Why Buy DNTH? Key Strengths
- Strong balance sheet composition with $493.4M stockholders' equity and minimal debt (0.00x debt/equity ratio)
- Adequate short-term liquidity with 13.32x current ratio and $51.1M cash position
- Elevated insider activity (9 Form 4 filings in 90 days) may indicate management confidence in pipeline
DNTH Investment Risks to Consider
- Severe cash burn of $129.1M annually with only ~5 months of cash runway remaining
- Negligible revenue ($2M) relative to operating expenses indicates company is far from commercialization
- Extreme negative operating margins (-8739.3%) and net margins (-7973.3%) reflect pre-commercial stage with no near-term profitability path
- Negative free cash flow of -$129.3M indicates company is consuming capital at unsustainable rates
Key Metrics to Watch
- Monthly cash burn rate and runway calculation
- Clinical trial progress and pipeline advancement milestones
- Revenue growth trajectory and any progress toward commercialization
- Changes in stockholders' equity and cash position quarter-over-quarter
DNTH Financial Metrics
💡 AI Analyst Insight
Strong liquidity with a 13.32x current ratio provides a solid financial cushion.
DNTH Profitability Ratios
DNTH vs Healthcare Sector
How Dianthus Therapeutics, Inc. /DE/ compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is DNTH Overvalued or Undervalued?
Based on fundamental analysis, Dianthus Therapeutics, Inc. /DE/ has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
DNTH Balance Sheet & Liquidity
DNTH 5-Year Financial Trend & Growth Analysis
5-Year Trend Summary: Dianthus Therapeutics, Inc. /DE/'s revenue has remained relatively flat over the 5-year period, with a 0% decline. The most recent EPS of $-2.55 indicates the company is currently unprofitable.
DNTH Growth Metrics (YoY)
DNTH Quarterly Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2025 | $396.0K | -$13.7M | $-0.74 |
| Q2 2025 | $193.0K | -$13.7M | $-0.51 |
| Q1 2025 | $874.0K | -$13.7M | $-0.54 |
| Q3 2023 | $924.0K | -$4.9M | $-3.78 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
DNTH Capital Allocation
DNTH SEC 10-K & 10-Q Filing Analysis
Access official SEC EDGAR filings for Dianthus Therapeutics, Inc. /DE/ (CIK: 0001690585)
📋 Recent SEC Filings
❓ Frequently Asked Questions about DNTH
What is the AI rating for DNTH?
Dianthus Therapeutics, Inc. /DE/ (DNTH) has an AI rating of STRONG SELL with 92% confidence, based on fundamental analysis of SEC EDGAR filings.
What are DNTH's key strengths?
Claude: Strong balance sheet composition with $493.4M stockholders' equity and minimal debt (0.00x debt/equity ratio). Adequate short-term liquidity with 13.32x current ratio and $51.1M cash position.
What are the risks of investing in DNTH?
Claude: Severe cash burn of $129.1M annually with only ~5 months of cash runway remaining. Negligible revenue ($2M) relative to operating expenses indicates company is far from commercialization.
What is DNTH's revenue and growth?
Dianthus Therapeutics, Inc. /DE/ reported revenue of $2.0M.
Does DNTH pay dividends?
Dianthus Therapeutics, Inc. /DE/ does not currently pay dividends.
Where can I find DNTH SEC filings?
Official SEC filings for Dianthus Therapeutics, Inc. /DE/ (CIK: 0001690585) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is DNTH's EPS?
Dianthus Therapeutics, Inc. /DE/ has a diluted EPS of $-4.20.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is DNTH a good stock to buy right now?
Based on our AI fundamental analysis in March 2026, Dianthus Therapeutics, Inc. /DE/ has a STRONG SELL rating with 92% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is DNTH stock overvalued or undervalued?
Valuation metrics for DNTH: ROE of -32.9% (sector avg: 15%), net margin of -7,973.3% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy DNTH stock in 2026?
Our dual AI analysis gives Dianthus Therapeutics, Inc. /DE/ a combined STRONG SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is DNTH's free cash flow?
Dianthus Therapeutics, Inc. /DE/'s operating cash flow is $-129.1M, with capital expenditures of $245.0K. FCF margin is -6,350.9%.
How does DNTH compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin -7,973.3% (avg: 12%), ROE -32.9% (avg: 15%), current ratio 13.32 (avg: 2).